Insulin Resistance Predicts Severity of Coronary Atherosclerotic Disease in Non-Diabetic Patients.
cardiovascular prevention
coronary atherosclerosis
insulin resistance
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
07 Jul 2020
07 Jul 2020
Historique:
received:
21
05
2020
revised:
23
06
2020
accepted:
27
06
2020
entrez:
11
7
2020
pubmed:
11
7
2020
medline:
11
7
2020
Statut:
epublish
Résumé
Insulin resistance (IR) in patients with type 2 diabetes mellitus (T2DM) represents a predictor of coronary artery disease (CAD). However, how IR is able to impact the severity of coronary atherosclerosis in non-diabetic patients is unknown. We investigated the relation between the IR and the extent and severity of coronary atherosclerosis in non-diabetic patients referred to coronary angiography (CA) Methods: Consecutive patients undergoing to CA for acute coronary syndromes or stable angina were analyzed. The IR was assessed by mean of the homeostasis model assessment of insulin resistance (HOMA-IR) whereas the SYNTAX score (SS) was used as index of the severity of coronary atherosclerosis Results: Overall, 126 patients were included, with a median SS of 12 (IQR 5.25-20.5). Patients were divided in four groups according to the distribution in quartiles of SS (SS1-2-3-4). A significant correlation between HOMA-IR and SS was observed, especially in women. A progressive increase of HOMA-IR was observed in parallel with the increasing severity (from SS1 to SS4) and extension (1-2-3-vessel disease) of coronary atherosclerosis. Multivariable analysis showed that the HOMA-IR was the strongest independent predictor of severe (SS4) and extensive (three-vessel disease) coronary atherosclerosis. Insulin resistance goes hand in hand with the extension and severity of coronary atherosclerosis in non-diabetic patients. The HOMA index is an independent predictor of three-vessel disease at CA. The HOMA index could be useful for risk stratification of CAD even in absence of T2DM.
Sections du résumé
BACKGROUND
BACKGROUND
Insulin resistance (IR) in patients with type 2 diabetes mellitus (T2DM) represents a predictor of coronary artery disease (CAD). However, how IR is able to impact the severity of coronary atherosclerosis in non-diabetic patients is unknown.
OBJECTIVES
OBJECTIVE
We investigated the relation between the IR and the extent and severity of coronary atherosclerosis in non-diabetic patients referred to coronary angiography (CA) Methods: Consecutive patients undergoing to CA for acute coronary syndromes or stable angina were analyzed. The IR was assessed by mean of the homeostasis model assessment of insulin resistance (HOMA-IR) whereas the SYNTAX score (SS) was used as index of the severity of coronary atherosclerosis Results: Overall, 126 patients were included, with a median SS of 12 (IQR 5.25-20.5). Patients were divided in four groups according to the distribution in quartiles of SS (SS1-2-3-4). A significant correlation between HOMA-IR and SS was observed, especially in women. A progressive increase of HOMA-IR was observed in parallel with the increasing severity (from SS1 to SS4) and extension (1-2-3-vessel disease) of coronary atherosclerosis. Multivariable analysis showed that the HOMA-IR was the strongest independent predictor of severe (SS4) and extensive (three-vessel disease) coronary atherosclerosis.
CONCLUSION
CONCLUSIONS
Insulin resistance goes hand in hand with the extension and severity of coronary atherosclerosis in non-diabetic patients. The HOMA index is an independent predictor of three-vessel disease at CA. The HOMA index could be useful for risk stratification of CAD even in absence of T2DM.
Identifiants
pubmed: 32646007
pii: jcm9072144
doi: 10.3390/jcm9072144
pmc: PMC7408744
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Diabetol Metab Syndr. 2015 Nov 14;7:100
pubmed: 26753001
Curr Atheroscler Rep. 2014 Jun;16(6):417
pubmed: 24764181
Am J Cardiol. 2017 Jul 1;120(1):106-110
pubmed: 28483203
Diabetes Care. 2002 Jul;25(7):1135-41
pubmed: 12087010
Diabetes Care. 2012 Aug;35(8):1787-94
pubmed: 22699296
Eur Heart J. 2016 Oct 14;37(39):2999-3058
pubmed: 27567407
Eur Heart J. 2013 Nov;34(44):3419-26
pubmed: 23882068
Diabetes Care. 1992 Jul;15(7):815-9
pubmed: 1516497
J Hypertens. 2018 Oct;36(10):1953-2041
pubmed: 30234752
EuroIntervention. 2005 Aug;1(2):219-27
pubmed: 19758907
Circulation. 1998 Aug 4;98(5):398-404
pubmed: 9714089
N Am J Med Sci. 2013 Oct;5(10):611-4
pubmed: 24350075
Int J Mol Sci. 2019 Mar 30;20(7):
pubmed: 30935055
Diabet Med. 1999 May;16(5):442-3
pubmed: 10342346
Am J Med. 2007 Mar;120(3 Suppl 1):S12-8
pubmed: 17320517
BMC Neurol. 2019 Jul 25;19(1):177
pubmed: 31345181
JAMA. 1990 Jun 6;263(21):2893-8
pubmed: 2338751
Hypertens Res. 2011 Feb;34(2):232-8
pubmed: 21124323
N Engl J Med. 1998 Jul 23;339(4):229-34
pubmed: 9673301
Diabetes Care. 2013 Jan;36 Suppl 1:S67-74
pubmed: 23264425
Arch Neurol. 2010 Oct;67(10):1195-200
pubmed: 20937946
Cardiovasc Diabetol. 2018 Jun 8;17(1):83
pubmed: 29884191
J Womens Health (Larchmt). 2005 Mar;14(2):137-45
pubmed: 15775731
Trends Cardiovasc Med. 2006 Aug;16(6):183-8
pubmed: 16839860
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):295-301
pubmed: 12588774
Diabetes Care. 2001 Feb;24(2):362-5
pubmed: 11213893
J Clin Med. 2019 Jul 21;8(7):
pubmed: 31330868